Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 8 of 11
Mar 3, 2026In the rapidly evolving healthcare AI sector, investors are shifting their focus towards tangible returns amid heightened market scrutiny. This post explores the insights from four prominent venture capitalists on what matters most for AI startups to succeed in today's environment.
Dr. Priya Nandakumar
Mar 1, 2026In an effort to address the burden of rising prescription drug costs, GoodRx rolls out a program that allows employers to subsidize brand medication prices directly. This strategy aims to enhance medication affordability for employees while maintaining the status quo of employer health insurance plans.
Jonathan Blake
Feb 27, 2026Founded by Flagship Pioneering, Generate Biomedicines aims to revolutionize severe asthma treatment with a novel therapeutic designed using advanced AI and machine learning. This new drug promises less frequent injections compared to existing blockbuster therapies developed by leading pharmaceutical companies.
Daniel Cho
Feb 27, 2026At the recent JPM26 conference, BioSpace captured the pulse of the healthcare industry, examining key trends in biotech innovation, regulatory changes, and investment flows. This detailed report examines the implications for investors, companies, and policy makers navigating a rapidly evolving landscape.
Emily Carter
Feb 25, 2026In a significant advancement for pediatric healthcare delivery, Coral Care secured $13 million in Series A funding led by Haymaker Ventures. This investment aims to scale Coral Care's innovative in-home therapy services for children, improving access and outcomes for young patients suffering from developmental and physical challenges. The funding round attracted multiple strategic investors, underlining confidence in Coral Care's mission to transform pediatric care.
Jonathan Blake
Feb 23, 2026Healthcare leaders highlight at a recent ViVE conference that sustaining rural hospitals is critical to preserving economic vitality as well as ensuring access to essential care for rural populations. The multifaceted rural healthcare crisis requires attention beyond medical concerns to economic policy and infrastructure.
Daniel Cho
Feb 22, 2026The recent acquisition positions Hims & Hers to broaden its footprint beyond traditional markets, signaling strategic moves to mitigate domestic regulatory pressures affecting GLP-1 therapies. This analysis explores the acquisition's implications on the company's growth trajectory and its broader market impact.
Emily Carter
Feb 20, 2026As the healthcare system increasingly adjusts to novel CMS payment and care delivery standards, startups like Rainfall Health are positioned to support hospitals through these transitions. Their recent $15 million funding round, led by Two Bear Capital, underscores the critical intersection of technology, policy, and hospital operations.
Emily Carter
Feb 20, 2026Frist Cressey Ventures recently secured $425 million in its fourth fund to back promising early-stage healthcare startups. The fund targets companies leveraging artificial intelligence to enhance healthcare delivery, reduce costs, and address challenges related to the aging population.
Dr. Alex Morgan
Feb 19, 2026This initiative marks a significant stride in connecting patients with holistic digital mental health, coaching, and therapy services offered by Calm and Lyra Health. The network aims to address growing behavioral health needs through accessible and innovative digital platforms.
Dr. Alex Morgan
Feb 18, 2026PitchBook's analysis reveals that $33.8 billion was invested in biopharma during 2025, predominantly directed to companies with advanced stage programs close to clinical implementation. Early-stage firms are facing significant hurdles in securing venture funding amid rising concerns over risk and regulatory uncertainty.
Dr. Priya Nandakumar
Feb 16, 2026Medicare Advantage, a key segment in the healthcare insurance landscape, has experienced dwindling membership growth as several leading insurers, including UnitedHealth, Humana, and Aetna, have been actively reducing their rolls. This development follows a series of changes affecting the program and could signal a major shift in the sector.
Dr. Priya NandakumarMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.